These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 28124506)

  • 41. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial.
    Pratley RE; Nauck M; Bailey T; Montanya E; Cuddihy R; Filetti S; Thomsen AB; Søndergaard RE; Davies M;
    Lancet; 2010 Apr; 375(9724):1447-56. PubMed ID: 20417856
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effectiveness and Persistence with Liraglutide Among Patients with Type 2 Diabetes in Routine Clinical Practice--EVIDENCE: A Prospective, 2-Year Follow-Up, Observational, Post-Marketing Study.
    Gautier JF; Martinez L; Penfornis A; Eschwège E; Charpentier G; Huret B; Madani S; Gourdy P
    Adv Ther; 2015 Sep; 32(9):838-53. PubMed ID: 26424330
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets.
    DeVries JH; Bain SC; Rodbard HW; Seufert J; D'Alessio D; Thomsen AB; Zychma M; Rosenstock J;
    Diabetes Care; 2012 Jul; 35(7):1446-54. PubMed ID: 22584132
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The effect of addition of liraglutide to high-dose intensive insulin therapy: a randomized prospective trial.
    Lane W; Weinrib S; Rappaport J; Hale C
    Diabetes Obes Metab; 2014 Sep; 16(9):827-32. PubMed ID: 24589127
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical effectiveness of liraglutide across body mass index in patients with type 2 diabetes in the United States: a retrospective cohort study.
    Chitnis AS; Ganz ML; Benjamin N; Langer J; Hammer M
    Adv Ther; 2014 Sep; 31(9):986-99. PubMed ID: 25245811
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease.
    Feng W; Gao C; Bi Y; Wu M; Li P; Shen S; Chen W; Yin T; Zhu D
    J Diabetes; 2017 Aug; 9(8):800-809. PubMed ID: 28332301
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy.
    Dutour A; Abdesselam I; Ancel P; Kober F; Mrad G; Darmon P; Ronsin O; Pradel V; Lesavre N; Martin JC; Jacquier A; Lefur Y; Bernard M; Gaborit B
    Diabetes Obes Metab; 2016 Sep; 18(9):882-91. PubMed ID: 27106272
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Epicardial adipose tissue and residual cardiovascular risk: a comprehensive case analysis and therapeutic insights with Liraglutide.
    Cacciapuoti F; Mauro C; D'Andrea D; Capone V; Liguori C; Cacciapuoti F
    J Cardiovasc Med (Hagerstown); 2024 Aug; 25(8):637-641. PubMed ID: 38916237
    [No Abstract]   [Full Text] [Related]  

  • 49. Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10).
    Capehorn MS; Catarig AM; Furberg JK; Janez A; Price HC; Tadayon S; Vergès B; Marre M
    Diabetes Metab; 2020 Apr; 46(2):100-109. PubMed ID: 31539622
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Liraglutide achieves A1C targets more often than sitagliptin or exenatide when added to metformin in patients with type 2 diabetes and a baseline A1C <8.0%.
    King AB; Montanya E; Pratley RE; Blonde L; Svendsen CB; Donsmark M; Sesti G
    Endocr Pract; 2013; 19(1):64-72. PubMed ID: 23186975
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Twelve-month treatment with Liraglutide ameliorates Visceral Adiposity Index and common cardiovascular risk factors in type 2 diabetes outpatients.
    Russo GT; Labate AM; Giandalia A; Romeo EL; Villari P; Alibrandi A; Perdichizzi G; Cucinotta D
    J Endocrinol Invest; 2015 Jan; 38(1):81-9. PubMed ID: 25173876
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Review of the therapeutic uses of liraglutide.
    Ryan GJ; Foster KT; Jobe LJ
    Clin Ther; 2011 Jul; 33(7):793-811. PubMed ID: 21741090
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Insulin tolerance test predicts non response vs. sustained efficacy of Liraglutide on glycemic control in type 2 diabetes patients: A prospective real-world setting study.
    Germain N; Khalfallah Y; Estour B; Galusca B
    Diabetes Res Clin Pract; 2018 Mar; 137():20-27. PubMed ID: 29253625
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study.
    Pratley RE; Nauck MA; Barnett AH; Feinglos MN; Ovalle F; Harman-Boehm I; Ye J; Scott R; Johnson S; Stewart M; Rosenstock J;
    Lancet Diabetes Endocrinol; 2014 Apr; 2(4):289-297. PubMed ID: 24703047
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease.
    Yan J; Yao B; Kuang H; Yang X; Huang Q; Hong T; Li Y; Dou J; Yang W; Qin G; Yuan H; Xiao X; Luo S; Shan Z; Deng H; Tan Y; Xu F; Xu W; Zeng L; Kang Z; Weng J
    Hepatology; 2019 Jun; 69(6):2414-2426. PubMed ID: 30341767
    [TBL] [Abstract][Full Text] [Related]  

  • 56. GLP-1 analogue-induced weight loss does not improve obesity-induced AT dysfunction.
    Pastel E; McCulloch LJ; Ward R; Joshi S; Gooding KM; Shore AC; Kos K
    Clin Sci (Lond); 2017 Mar; 131(5):343-353. PubMed ID: 28049736
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).
    Buse JB; Rosenstock J; Sesti G; Schmidt WE; Montanya E; Brett JH; Zychma M; Blonde L;
    Lancet; 2009 Jul; 374(9683):39-47. PubMed ID: 19515413
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients.
    Smits MM; Tonneijck L; Muskiet MH; Hoekstra T; Kramer MH; Diamant M; Nieuwdorp M; Groen AK; Cahen DL; van Raalte DH
    Diabetes Obes Metab; 2016 Dec; 18(12):1217-1225. PubMed ID: 27451030
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A randomized controlled trial comparing the GLP-1 receptor agonist liraglutide to a sulphonylurea as add on to metformin in patients with established type 2 diabetes during Ramadan: the Treat 4 Ramadan Trial.
    Brady EM; Davies MJ; Gray LJ; Saeed MA; Smith D; Hanif W; Khunti K
    Diabetes Obes Metab; 2014 Jun; 16(6):527-36. PubMed ID: 24373063
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical use of liraglutide in type 2 diabetes and its effects on cardiovascular risk factors.
    Varanasi A; Patel P; Makdissi A; Dhindsa S; Chaudhuri A; Dandona P
    Endocr Pract; 2012; 18(2):140-5. PubMed ID: 21856595
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.